INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is an MMJ stock that has truly been on quite an adventure over the past few months, rocketing up to nearly $0.75/share from the lowly depths of less than a dime just few months earlier, and then sinking back down to the quarter level before bouncing back higher. The company has been hard at work, pushing its strengths to the investing public. But this is a long-game opportunity, which means it will always be full of ups and downs.
The latest from the company comes in the form of its announcement on Tuesday of results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav). “Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward”, said Eric A. Adams, President & CEO of InMed. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) casts itself as a biopharmaceutical company specializing in developing cannabis-based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
IMLFF is utilizing its proprietary Intelligent Cannabinoid Drug Design Platform to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific diseases.
The big picture is that this is a pre-clinical stage biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based therapies to treat human diseases with high unmet medical needs. The Company has three core assets: a proprietary Bioinformatics assessment tool to match individual (or combination of) cannabinoids against disease targets; a proprietary Biosynthesis cannabinoid manufacturing system to economically produce all 90+ cannabinoids at pharmaceutical-grade (>99.5% purity); and drug development program enabled by the two aforementioned tools. Leaders in the pipeline include a treatment for the symptoms and, potentially, the underlying disease in Epidermolysis Bullosa, a rare, devastating genetic skin disorder; and, a once-a-day eyedrops formulation of cannabinoids to treat Glaucoma, one of the leading causes of blindness in the developed world.
According to company materials, “InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.”
Find out when $IMLFF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, IMLFF shares are reacting to the company’s next step in establishing its long game in the MMJ space.
According to its most recent release, this particular InMed study (the collaboration InMed-UBC study) is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, resulting in enhanced drug uptake via the cornea and lens.
“This study further validates the Company’s capacity to conduct a wide spectrum of drug development activities, including biosynthesis of a cannabinoid using a novel E. coli-based system, packaging the cannabinoid as a nanoparticle, formulation of a cannabinoid drug candidate into a novel, tissue-specific delivery vehicle, and confirmation of drug delivery and diffusion into a target tissue.”
Recent action has seen 5% added to share values of the name over the past week of action. The situation may be worth watching. IMLFF has evidenced sudden upward volatility on many prior occasions. Furthermore, the stock has seen a growing influx of trading interest, with the stock’s recent average trading volume running 54% beyond what we have been seeing over the larger time frame.
Earning a current market cap value of $45.6M, IMLFF has a significant war chest ($6.7M) of cash on the books, which compares with virtually no total current liabilities. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $IMLFF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $IMLFF, either long or short, and we have not been compensated for this article.